<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Medtronic Plc — News on 6ix</title>
<link>https://6ix.com/company/medtronic-plc</link>
<description>Latest news and press releases for Medtronic Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 08:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/medtronic-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835973f78dffbe2df104e67.webp</url>
<title>Medtronic Plc</title>
<link>https://6ix.com/company/medtronic-plc</link>
</image>
<item>
<title>Medtronic announces CE Mark for Stealth AXiS™ surgical system</title>
<link>https://6ix.com/company/medtronic-plc/news/medtronic-announces-ce-mark-for-stealth-axistm-surgical-system</link>
<guid isPermaLink="true">https://6ix.com/company/medtronic-plc/news/medtronic-announces-ce-mark-for-stealth-axistm-surgical-system</guid>
<pubDate>Tue, 28 Apr 2026 08:00:00 GMT</pubDate>
<description>Medtronic, a global leader in healthcare technology, has received CE mark for the Stealth AXiS™ surgical system, a next-generation platform that brings planning, navigation, and robotics together into one single, intelligent system. The Stealth AXiS™ system is indicated for spine and cranial procedures, highlighting the platform's scalability across multiple surgical specialties for Medtronic.</description>
</item>
<item>
<title>Medtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continues</title>
<link>https://6ix.com/company/medtronic-plc/news/medtronic-announces-key-afferatm-clinical-study-milestones-for-sphere-9tm-and-sphere-360tm-catheters-as-global-adoption-continues</link>
<guid isPermaLink="true">https://6ix.com/company/medtronic-plc/news/medtronic-announces-key-afferatm-clinical-study-milestones-for-sphere-9tm-and-sphere-360tm-catheters-as-global-adoption-continues</guid>
<pubDate>Sat, 25 Apr 2026 16:30:00 GMT</pubDate>
<description>Medtronic plc, (NYSE: MDT), a global leader in healthcare technology, today announced continued momentum for the Affera™ family of technologies for cardiac arrhythmia treatment, including promising data presented at the Heart Rhythm Society (HRS) Annual Meeting and the start of a new trial to evaluate a broader population of atrial fibrillation (AFib) patients. With ongoing positive physician feedback and global commercial expansion, Medtronic continues to invest in clinical research to study th</description>
</item>
<item>
<title>2026 HoustonCISO ORBIE Awards Recognize Top Security Executives</title>
<link>https://6ix.com/company/medtronic-plc/news/2026-houstonciso-orbie-awards-recognize-top-security-executives</link>
<guid isPermaLink="true">https://6ix.com/company/medtronic-plc/news/2026-houstonciso-orbie-awards-recognize-top-security-executives</guid>
<pubDate>Thu, 23 Apr 2026 17:38:00 GMT</pubDate>
<description>Leading CISOs honored for leadership, enterprise security, and business impact. HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- The 2026 HoustonCISO ORBIE Awards honored leading chief information security officers (CISOs) from Medtronic, Nabors Industries, Texas Children’s Hospital (fmr), City of Houston, Cornerstone OnDemand, Odfjell Terminals USA, Inc., & SLB for their exceptional leadership. Hosted by HoustonCISO, a chapter of the Inspire Leadership Network, the prestigious awards honor CISOs who</description>
</item>
<item>
<title>VSI® Surgeons Perform World's First Spine Surgery with Stealth AXiS™ Autopilot Robotic System</title>
<link>https://6ix.com/company/medtronic-plc/news/vsir-surgeons-perform-worlds-first-spine-surgery-with-stealth-axistm-autopilot-robotic-system</link>
<guid isPermaLink="true">https://6ix.com/company/medtronic-plc/news/vsir-surgeons-perform-worlds-first-spine-surgery-with-stealth-axistm-autopilot-robotic-system</guid>
<pubDate>Tue, 21 Apr 2026 19:22:00 GMT</pubDate>
<description>VSI, one of the nation's leading spine centers, announced today that spine surgeons Drs. Christopher Good, Colin Haines, and Ehsan Jazini are the first in the world to perform surgery using Medtronic's FDA-cleared Stealth AXiS Autopilot surgical system. This next-generation platform marks a major advancement in robotic spine surgery, combining AI-powered surgical planning, segmental tracking, navigation, and robotics into a single platform. The integrated technology represents a shift toward mor</description>
</item>
<item>
<title>Wearable Injectors Market Report 2026 (8th Edition) Featuring Analysis of BD, Enable Injections, Insulet, Medtronic, Tandem Diabetes Care, West Pharmaceutical Services, and Ypsomed</title>
<link>https://6ix.com/company/medtronic-plc/news/wearable-injectors-market-report-2026-8th-edition-featuring-analysis-of-bd-enable-injections-insulet-medtronic-tandem-diabetes-care-west-pharmaceutical-services-and-ypsomed</link>
<guid isPermaLink="true">https://6ix.com/company/medtronic-plc/news/wearable-injectors-market-report-2026-8th-edition-featuring-analysis-of-bd-enable-injections-insulet-medtronic-tandem-diabetes-care-west-pharmaceutical-services-and-ypsomed</guid>
<pubDate>Tue, 21 Apr 2026 09:50:00 GMT</pubDate>
<description>Key market opportunities include the growing demand for home healthcare solutions due to rising chronic diseases Wearable Injectors Market Wearable Injectors Market Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Wearable Injectors Market (8th Edition): Distribution by Type of Device, Degree of Automation, Usability, Therapeutic Area, and Geographical Regions - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering.The global wearable injectors market is set to expand</description>
</item>
<item>
<title>Medtronic completes acquisition of CathWorks, expanding its leadership in transforming care for patients with cardiovascular disease</title>
<link>https://6ix.com/company/medtronic-plc/news/medtronic-completes-acquisition-of-cathworks-expanding-its-leadership-in-transforming-care-for-patients-with-cardiovascular-disease</link>
<guid isPermaLink="true">https://6ix.com/company/medtronic-plc/news/medtronic-completes-acquisition-of-cathworks-expanding-its-leadership-in-transforming-care-for-patients-with-cardiovascular-disease</guid>
<pubDate>Mon, 20 Apr 2026 11:50:00 GMT</pubDate>
<description>Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has completed its acquisition of CathWorks, a privately held medical device company, which aims to transform how coronary artery disease (CAD) is diagnosed and treated. The acquisition follows a 2022 strategic partnership with a co-promotion agreement for the CathWorks FFRangio® System where it is commercially available in the U.S., Europe and Japan. The acquisition is valued at $585 million with potential und</description>
</item>
<item>
<title>Pulnovo Medical Announces Strategic Investment from Medtronic in oversubscribed $100 Million Financing Round</title>
<link>https://6ix.com/company/medtronic-plc/news/pulnovo-medical-announces-strategic-investment-from-medtronic-in-oversubscribed-dollar100-million-financing-round</link>
<guid isPermaLink="true">https://6ix.com/company/medtronic-plc/news/pulnovo-medical-announces-strategic-investment-from-medtronic-in-oversubscribed-dollar100-million-financing-round</guid>
<pubDate>Mon, 20 Apr 2026 00:00:00 GMT</pubDate>
<description>Pulnovo Medical, a pioneer in breakthrough therapies for treating Pulmonary Hypertension and Heart Failure, today announced the successful completion of an oversubscribed $100 million strategic financing round with a leading investment by Medtronic, one of the world's largest medical technology companies, alongside continued support from existing investors such as EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, and Lilly Asia Ventures. Pulnovo also welcomes new investors, including HSG</description>
</item>
<item>
<title>Medtronic to announce financial results for its fourth quarter and full fiscal year 2026</title>
<link>https://6ix.com/company/medtronic-plc/news/medtronic-to-announce-financial-results-for-its-fourth-quarter-and-full-fiscal-year-2026</link>
<guid isPermaLink="true">https://6ix.com/company/medtronic-plc/news/medtronic-to-announce-financial-results-for-its-fourth-quarter-and-full-fiscal-year-2026</guid>
<pubDate>Mon, 13 Apr 2026 10:00:00 GMT</pubDate>
<description>Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Wednesday, June 3, 2026, for its fourth quarter and full fiscal year 2026, which ends on Friday, April 24, 2026.</description>
</item>
<item>
<title>/C O R R E C T I O N -- CIRCA SCIENTIFIC, LLC/</title>
<link>https://6ix.com/company/medtronic-plc/news/c-o-r-r-e-c-t-i-o-n-circa-scientific-llc</link>
<guid isPermaLink="true">https://6ix.com/company/medtronic-plc/news/c-o-r-r-e-c-t-i-o-n-circa-scientific-llc</guid>
<pubDate>Thu, 09 Apr 2026 14:36:00 GMT</pubDate>
<description>CIRCA Scientific today announced the appointment of Vafa Jamali, an accomplished medical technology executive with more than 30 years of industry leadership experience, to its Board of Directors.</description>
</item>
<item>
<title>Tempus and Medtronic Announce ALERT Trial Results Showing AI-Driven EHR Notifications Improve Treatment for Significant Valvular Heart Disease</title>
<link>https://6ix.com/company/medtronic-plc/news/tempus-and-medtronic-announce-alert-trial-results-showing-ai-driven-ehr-notifications-improve-treatment-for-significant-valvular-heart-disease-1</link>
<guid isPermaLink="true">https://6ix.com/company/medtronic-plc/news/tempus-and-medtronic-announce-alert-trial-results-showing-ai-driven-ehr-notifications-improve-treatment-for-significant-valvular-heart-disease-1</guid>
<pubDate>Wed, 01 Apr 2026 12:30:00 GMT</pubDate>
<description>CHICAGO, April 01, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from the ALERT (Addressing undertreatment and heaLth Equity in aortic stenosis and mitral regurgitation using an integrated ehR plaTform) trial, which were recently presented at the American College of Cardiology’s 75th Annual Scientific Session & Expo. The study, conducted in collaboration with Medtronic, found that automated electronic c</description>
</item>
<item>
<title>Medtronic Receives FDA Clearance for Stealth AXiS™ Surgical System for Cranial and ENT Procedures</title>
<link>https://6ix.com/company/medtronic-plc/news/medtronic-receives-fda-clearance-for-stealth-axistm-surgical-system-for-cranial-and-ent-procedures</link>
<guid isPermaLink="true">https://6ix.com/company/medtronic-plc/news/medtronic-receives-fda-clearance-for-stealth-axistm-surgical-system-for-cranial-and-ent-procedures</guid>
<pubDate>Fri, 27 Mar 2026 13:00:00 GMT</pubDate>
<description>Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance of the Stealth AXiS™ surgical system for cranial and ear, nose, and throat (ENT) procedures. Cleared for spine procedures in February, the Stealth AXiS™ surgical system unifies surgical planning, navigation, and robotics into a single intelligent system to support surgeons with greater precision and real-time insights during complex procedures. This clearance reinfor</description>
</item>
<item>
<title>Medtronic and Merit Medical Systems enter into agreement to offer new, FDA-cleared ViaVerte™ system, a basivertebral nerve ablation treatment for chronic vertebrogenic lower-back pain</title>
<link>https://6ix.com/company/medtronic-plc/news/medtronic-and-merit-medical-systems-enter-into-agreement-to-offer-new-fda-cleared-viavertetm-system-a-basivertebral-nerve-ablation-treatment-for-chronic-vertebrogenic-lower-back-pain-1</link>
<guid isPermaLink="true">https://6ix.com/company/medtronic-plc/news/medtronic-and-merit-medical-systems-enter-into-agreement-to-offer-new-fda-cleared-viavertetm-system-a-basivertebral-nerve-ablation-treatment-for-chronic-vertebrogenic-lower-back-pain-1</guid>
<pubDate>Tue, 24 Mar 2026 12:30:00 GMT</pubDate>
<description>Medtronic plc, a global leader in healthcare technology, today announced that it has entered into a distribution agreement with Merit Medical Systems, Inc. (NASDAQ: MMSI), to offer FDA-cleared ViaVerte™ — a minimally invasive and implant free basivertebral nerve ablation (BVNA) system. It is the first and only BVNA system with a physician-controlled steerable mechanism for precise basivertebral nerve targeting for treating chronic vertebrogenic lower back pain. This agreement continues Medtronic</description>
</item>
<item>
<title>Medtronic OmniaSecure™ defibrillation lead is the first lead of its kind to receive FDA approval for conduction system pacing</title>
<link>https://6ix.com/company/medtronic-plc/news/medtronic-omniasecuretm-defibrillation-lead-is-the-first-lead-of-its-kind-to-receive-fda-approval-for-conduction-system-pacing</link>
<guid isPermaLink="true">https://6ix.com/company/medtronic-plc/news/medtronic-omniasecuretm-defibrillation-lead-is-the-first-lead-of-its-kind-to-receive-fda-approval-for-conduction-system-pacing</guid>
<pubDate>Mon, 23 Mar 2026 13:00:00 GMT</pubDate>
<description>Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for an expanded indication for the OmniaSecure™ defibrillation lead. Now approved for placement in the left bundle branch (LBB) area, the lead can be used for conduction system pacing (CSP), which closely mimics the heart's natural physiology. Additionally, patients in need of cardiac resynchronization may benefit from left bundle branch optimized cardiac resynchronizati</description>
</item>
<item>
<title>ACCESS GPO Announces Preferred Strategic Commercial Agreement to Provide Affera™ Mapping and Ablation System with Sphere-9™ Catheter to Ambulatory Surgery Centers</title>
<link>https://6ix.com/company/medtronic-plc/news/access-gpo-announces-preferred-strategic-commercial-agreement-to-provide-afferatm-mapping-and-ablation-system-with-sphere-9tm-catheter-to-ambulatory-surgery-centers</link>
<guid isPermaLink="true">https://6ix.com/company/medtronic-plc/news/access-gpo-announces-preferred-strategic-commercial-agreement-to-provide-afferatm-mapping-and-ablation-system-with-sphere-9tm-catheter-to-ambulatory-surgery-centers</guid>
<pubDate>Fri, 13 Mar 2026 14:26:00 GMT</pubDate>
<description>NEW YORK, March 13, 2026--ACCESS GPO today announced a preferred, multi-year agreement with Medtronic to support availability of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter in ambulatory surgery centers (ASCs) across the United States. The agreement is designed to help physician-led ASCs gain earlier access to next-generation technology for treatment of cardiac arrhythmias in the ASC setting.</description>
</item>
<item>
<title>Medtronic to acquire Scientia Vascular, marrying access and therapeutic portfolios for neurovascular care</title>
<link>https://6ix.com/company/medtronic-plc/news/medtronic-to-acquire-scientia-vascular-marrying-access-and-therapeutic-portfolios-for-neurovascular-care</link>
<guid isPermaLink="true">https://6ix.com/company/medtronic-plc/news/medtronic-to-acquire-scientia-vascular-marrying-access-and-therapeutic-portfolios-for-neurovascular-care</guid>
<pubDate>Tue, 10 Mar 2026 10:45:00 GMT</pubDate>
<description>Medtronic today announced its entry into a definitive agreement to acquire Scientia Vascular, a company with critical, innovative technology across the neurovascular portfolio. The acquisition is valued at $550 million, subject to customary adjustments, with potential undisclosed earn-out and milestone payments post-acquisition.</description>
</item>
<item>
<title>MiniMed announces closing of Initial Public Offering</title>
<link>https://6ix.com/company/medtronic-plc/news/minimed-announces-closing-of-initial-public-offering-1</link>
<guid isPermaLink="true">https://6ix.com/company/medtronic-plc/news/minimed-announces-closing-of-initial-public-offering-1</guid>
<pubDate>Mon, 09 Mar 2026 20:58:00 GMT</pubDate>
<description>MiniMed Group, Inc. (MiniMed; Nasdaq: MMED) today announced the closing of its previously announced initial public offering (IPO) of 28,000,000 shares of its common stock at a price to the public of $20.00 per share. The shares began trading on the Nasdaq Global Select Market (Nasdaq) on March 6, 2026 under the symbol "MMED."</description>
</item>
<item>
<title>MiniMed to begin trading on Nasdaq Global Select Market</title>
<link>https://6ix.com/company/medtronic-plc/news/minimed-to-begin-trading-on-nasdaq-global-select-market-12</link>
<guid isPermaLink="true">https://6ix.com/company/medtronic-plc/news/minimed-to-begin-trading-on-nasdaq-global-select-market-12</guid>
<pubDate>Fri, 06 Mar 2026 14:00:00 GMT</pubDate>
<description>Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced that MiniMed Group, Inc. (Nasdaq: MMED) will begin trading today on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol "MMED" in connection with its initial public offering ("IPO").</description>
</item>
<item>
<title>MiniMed announces pricing of initial public offering</title>
<link>https://6ix.com/company/medtronic-plc/news/minimed-announces-pricing-of-initial-public-offering-9</link>
<guid isPermaLink="true">https://6ix.com/company/medtronic-plc/news/minimed-announces-pricing-of-initial-public-offering-9</guid>
<pubDate>Fri, 06 Mar 2026 00:35:00 GMT</pubDate>
<description>MiniMed Group, Inc. (MiniMed), a subsidiary of Medtronic plc (Medtronic) (NYSE: MDT), today announced the pricing of its initial public offering (IPO) of 28,000,000 shares of its common stock at a price to the public of $20.00 per share. The shares are expected to begin trading on the Nasdaq Global Select Market (Nasdaq) on March 6, 2026, under the symbol "MMED." The offering is expected to close on March 9, 2026, subject to customary closing conditions.</description>
</item>
<item>
<title>Medtronic announces cash dividend for fourth quarter of fiscal year 2026</title>
<link>https://6ix.com/company/medtronic-plc/news/medtronic-announces-cash-dividend-for-fourth-quarter-of-fiscal-year-2026-18</link>
<guid isPermaLink="true">https://6ix.com/company/medtronic-plc/news/medtronic-announces-cash-dividend-for-fourth-quarter-of-fiscal-year-2026-18</guid>
<pubDate>Thu, 05 Mar 2026 21:53:00 GMT</pubDate>
<description>The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 5, 2026, approved the company's cash dividend for the fourth quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on April 17, 2026, to sh</description>
</item>
<item>
<title>Medtronic CFO Thierry Piéton to speak at upcoming investor conferences</title>
<link>https://6ix.com/company/medtronic-plc/news/medtronic-cfo-thierry-pieton-to-speak-at-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/medtronic-plc/news/medtronic-cfo-thierry-pieton-to-speak-at-upcoming-investor-conferences</guid>
<pubDate>Tue, 03 Mar 2026 15:31:00 GMT</pubDate>
<description>Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that Thierry Piéton, Medtronic executive vice president and chief financial officer, will participate in fireside chats at the following investor conferences:</description>
</item>
</channel>
</rss>